Affiliation:
1. Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Technische Universität Dresden, 01307 Dresden, Germany
2. Novartis Pharma GmbH, 90429 Nuremberg, Germany
3. Institute for Immunology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany
Abstract
Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod interruption (cohort 2), or during treatment with other disease-modifying therapies or without therapy (cohort 3). SARS-CoV-2-specific antibodies and T-cell reactivity were measured six months after the initial vaccination and one month after the booster. Results: 41 patients were recruited into cohort 1 (n = 17), cohort 2 (n = 4), and cohort 3 (n = 20). Seroconversion for SARS-CoV-2 neutralizing antibodies was reached by 50.0%, 100.0%, and 90.0% of patients at month 6 and by 81.3%, 100.0%, and 100.0% one month after booster (cohorts 1, 2, and 3, respectively). Antibody levels in cohort 1 increased after the booster compared to month 6 but remained lower compared to cohorts 2 and 3. T-cell responses were seen in 28.5%, 25.0%, and 73.7% at month 6 and in 28.6%, 50.0%, and 83.3% after the booster (cohorts 1, 2, and 3, respectively). In cohort 1, the extent of T-cell response was lower at month 6 compared to cohorts 2 and 3 but reached almost similar levels after the booster. Conclusions: The antibody and T-cell responses support SARS-CoV-2 (booster) vaccines in siponimod-treated patients.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference19 articles.
1. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study;Deepak;Ann. Intern. Med.,2021
2. Administration of COVID-19 vaccines in immunocompromised patients;Negahdaripour;Int. Immunopharmacol.,2021
3. Behrangi, N., Fischbach, F., and Kipp, M. (2019). Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells, 8.
4. European Medicines Agency (2022, March 29). Mayzent—Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf.
5. Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod;Rogic;Mult. Scler. Relat. Disord.,2022